I. Company Profile
Kunming SINOWAY Natural Pharmaceuticals Co., Ltd. (hereinafter referred to as the company) is a high-tech company in China that integrates the research and development, production, and sales of natural, chemical, and macro-molecular biological drugs. In recent years, the company has undergone a long-term stable operation, innovation, and development, and is now in the pre-listing tutoring period and in its third year of IPO, striving to be a listed company as soon as possible. Since its establishment in 1998, the company has been rooted in China and committed to advancing scientific and technological innovation with remarkable results achieved. In the critical period of industry changes and adjustments, the company has steadily carried out the R&D of immunotoxic antibody drugs by relying on its own R&D team and cooperating with Shanghai Jiaotong University. Despite the impact of COVID-19 in 2020, the company still realized a total turnover of nearly RMB 500 million and a profit exceeding RMB 100 million.
The company has obtained a total of 42 patents since its establishment. In 1985, it was the first company to successfully develop and declare "Kangfuxin", the first Chinese drug made from the extract of the insect Periplaneta americana, which is mainly used for the treatment of stomachache, bleeding, gastric and duodenal ulcers, and wounds. In 2000, it succeeded in researching and declaring the small-molecule chemical drug "Amlodipine Mesylate", which is mainly used for the treatment of hypertension and has become a famous brand in Yunnan with annual sales of RMB 200-300 million, obtaining the PCT international process patent in 2021. In 2005, the company successfully researched and declared another drug "Ganlong Capsule", which is used for the treatment of chronic hepatitis. The drug is also made from the extract of Periplaneta americana. In 2018, the company made a proposal to build a system of innovative drugs to be in line with international standards as soon as possible, and cooperated with Lab Jaco to enter the field of immunotoxic macro-molecular biologics.
At present, the company is gradually completing the construction platform of a new production base, the joint laboratory established with the School of Pharmacy of Shanghai Jiaotong University, and the platform construction of relevant projects carried out with Lab Jaco, USA. This empowers the company with stronger capability in R&D of new drugs and more experience in the declaration of experiments and marketing. In 2018, the project of "Discovery, Creation, and Industrialization Demonstration of a Series of New Drugs Derived from Periplaneta Americana" implemented and completed by the company won the first prize of Yunnan Provincial Scientific and Technological Progress Award. The product "Kangfuxin Solution" won the silver award of "Invention and Entrepreneurship Award - Project Award" at the 10th International Exhibition of Inventions & the 3rd World Invention and Innovation Forum. The product "Ganlong Capsule" won the silver award of "Invention and Entrepreneurship Award - Project Award" at the 10th International Exhibition of Inventions & the 3rd World Invention and Innovation Forum. In 2019, China Charity Federation awarded the "Certificate of Appreciation" for our company in the activity of "Contributing to the national battle against poverty in three regions and three prefectures for children with congenital heart defects from poor families and patients with hydatidosis in Tibetan areas". In the same year, the company was awarded the title of "Top 100 Private Enterprises in Yunnan Province". It also won the "2020 Best Platform Construction Award" by the China Medical Pharmaceutical Material Association and the "Certificate of Appreciation" by the General Association of Red Cross Society of China in 2020.
To support the company's strategic layout of R&D and innovation, the first phase of the company's planned new factory has been launched, with a total area of 66,000 square meters or about 99.268 mu (about 6.6 hectares), and a total project construction area of 73,000 square meters. After completion, our company will become a modern pharmaceutical company covering high-tech biomedicine and traditional medicine by integrating pharmaceutical innovation and R&D, modern production and manufacturing, and standardized testing.
The company has a nationwide sales network, with products covering all levels of terminals from large grade-A tertiary hospitals to county and community hospitals, as well as clinics and pharmacies, township health centers, etc. It has also signed strategic cooperation agreements with more than 20 famous chains in China. Thanks to the reasonable channel length, effective channel width and channel network covering all levels, quality products provided by SINOWAY can reach every medical service institution in China quickly and safely.
II. R&D Overview
1. The company has the first patent for the invention of Periplaneta americana extract and preparation products in China and even in the world. Three series of Periplaneta americana drugs have been approved and registered, namely Kangfuxin, Kangfuxin Solution, and Ganlong Capsule, of which the first two are the original research varieties developed by the company, mainly used for the treatment of gastric and duodenal ulcers and traumatic wounds. Ganlong Capsule is the original and exclusive product of the company and a national Class II new drug, mainly used for the treatment of chronic hepatitis B patients and hepatitis B virus carriers.
2. It is the first original research company that achieves mass production and market promotion of Periplaneta americana, and owns two registration approvals. It has nearly 40 years of experience to prove medication safety and clinical efficacy of Periplaneta americana series products. In the long-term clinical observation, it was found that Periplaneta americana has the ability to repair and regenerate cell damage and apoptosis.
3. The company cooperated with the joint laboratory of Shanghai Jiaotong University in R&D: Biomacromolecule drug - a new type of immunotoxic drug, SN-001 project The product is a novel humanized immunotoxin class 1 innovative biological drug. Its advantage lies in improving clinical efficacy by reducing immunogenicity and toxicity. No relevant studies or declarations have been made for this project in China.